Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Agios.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

Highlights of ASH®: New Frontiers in the Management of AML Treatment: The Emerging Role of Targeted Therapies - Seattle

Highlights of ASH®: New Frontiers in the Management of AML Treatment: The Emerging Role of Targeted Therapies - Seattle


PER Pulse™ Recap

Resources

Community Practice Connections™: Highlights of ASH®: New Frontiers in the Management of AML Treatment: The Emerging Role of Targeted Therapies
Earn up to 1.5 AMA PRA Category 1 Credits™
This activity focuses on emerging therapies for acute myeloid leukemia (AML). It features a series of short video interviews with leading experts in the field. The content and interviews are based on presentations given in January 2017 at New Frontiers in the Management of AML Treatment: The Emerging Role of Targeted Therapies, a series of live symposia that were held adjunct to the Highlights of ASH® in North America conferences in Seattle.

PER Pulse™ Recap
PER Pulse™ Recaps for Community Practice Connections™: Highlights of ASH®: New Frontiers in the Management of AML Treatment: The Emerging Role of Targeted Therapies focuses on areas of clinical challenge faced by practicing oncologists, along with emerging therapeutic approaches being developed to tackle these challenges.


 

PER Pulse™ Recap

PER Pulse™ Recap



1 of 3
PER Pulse™ Recap

Community Practice Connections™: Highlights of ASH®: New Frontiers in the Management of AML Treatment: The Emerging Role of Targeted Therapies is a series of short content summaries and video interviews with the faculty of a live CME-certified symposium held in January 2017 in Seattle, Washington. In this online activity, expert faculty discuss standards of care and emerging therapies for acute myeloid leukemia (AML). It features commentary on:

  • The biology of AML and its therapeutic implications by Daniel DeAngelo, MD, PhD
  • Potential therapeutic targets by Harry Erba, MD, PhD
  • Multikinase inhibition for FLT3-mutated AML by Daniel DeAngelo, MD, PhD
  • Evolving data sets and clinical trials of IDH inhibitors by Eytan Stein, MD
  • Optimization of outcomes for older adults by Harry Erba, MD, PhD
  • Rational drug combinations in AML by Eytan Stein, MD

This first of 3 PER Pulse™ Recaps summarizing the program focuses on Dr DeAngelo’s answers to questions about multikinase inhibition for FLT3-mutated AML.

Mutations in the FMS-like tyrosine kinase receptor gene (FLT3) are the most common genetic lesions found in AML. Patients with AML who harbor activating mutation(s) of FLT3 have a higher risk of relapse and poorer overall survival compared with patients with FLT3 wild-type AML. Current therapeutic goals for these patients include achieving first complete remission with induction chemotherapy followed by stem cell transplantation. Improved treatment options and outcomes for this group of patients represents a significant unmet need. Toward that end, researchers have been actively seeking to understand and characterize the biology of FLT3-positive AML and to develop therapeutics targeted to this subtype. During his interviews, Dr DeAngelo reviews and discusses ongoing studies of broad- and narrow-spectrum multikinase inhibitors in clinical trial for FLT3-mutated AML, including midostaurin, lestaurtinib, sorafenib, quizartinib, crenolanib, and gilteritinib.



2 of 3
PER Pulse™ Recap

Community Practice Connections™: Highlights of ASH®: New Frontiers in the Management of AML Treatment: The Emerging Role of Targeted Therapies is a series of short video interviews with the faculty of a live CME-certified symposium held in January 2017 in Seattle, Washington. In this online activity, expert faculty discuss standards of care and emerging therapies for acute myeloid leukemia (AML). It features commentary on:

  • The biology of AML and its therapeutic implications by Daniel DeAngelo, MD, PhD
  • Potential therapeutic targets by Harry Erba, MD, PhD
  • Multikinase inhibition for FLT3-mutated AML by Daniel DeAngelo, MD, PhD
  • Evolving data sets and clinical trials of IDH inhibitors by Eytan Stein, MD
  • Optimization of outcomes for older adults by Harry Erba, MD, PhD
  • Rational Drug Combinations in AML by Eytan Stein, MD

This second of 3 PER Pulse™ Recaps summarizing the program focuses on Dr Stein’s answers to questions about the development of IDH inhibitors for AML.

Mutations of the isocitrate dehydrogenase 1 or 2 (IDH1/2) genes are found in approximately 20% of adult patients with AML. Several IDH1/2 inhibitors are being investigated in clinical trial for AML. Of these, the IDH2 inhibitor enasidenib is furthest along. In phase II study, a 37% overall response rate was reported among patients with relapsed/refractory (R/R) AML who received enasidenib. Antitumor activity has also been demonstrated in early-phase studies of the IDH1 inhibitors AG-129 and IDH305. The Food and Drug Administration granted priority review to a new drug application for enasidenib as a treatment for IDH2-mutated, R/R AML. Dr Stein reviews data on these agents and discusses future directions with IDH inhibitors in AML, including their use in combination with standards of care and other targeted therapies.


3 of 3
PER Pulse™ Recap

Community Practice Connections™: Highlights of ASH®: New Frontiers in the Management of AML Treatment: The Emerging Role of Targeted Therapies is a series of short video interviews with the faculty of a live CME-certified symposium held in January 2017 in Seattle, WA. In this online activity, expert faculty discuss standards of care and emerging therapies for acute myeloid leukemia (AML). It features commentary on:

  • The biology of AML and its therapeutic implications by Daniel DeAngelo, MD, PhD
  • Potential therapeutic targets by Harry Erba, MD, PhD
  • Multikinase inhibition for FLT3-mutated AML by Daniel DeAngelo, MD, PhD
  • Evolving data sets and clinical trials of IDH inhibitors by Eytan Stein, MD
  • Optimization of outcomes for older adults by Harry Erba, MD, PhD
  • Rational Drug Combinations in AML by Eytan Stein, MD

This third of 3 PER Pulse™ Recaps summarizing the program focuses on Dr Erba’s answers to questions about optimizing outcomes for older patients with AML.

Most patients diagnosed with AML are aged ≥ 65 years. Significant improvements in outcomes of younger adults with AML have been realized over the past few decades. Unfortunately, outcomes for older adults have remained poor due to a variety of patient- and disease-related factors. The biology of AML in older adults differs from that of younger patients, featuring karyotypes and mutational profiles that are more adverse and complex. Dr Erba discusses standards of care for older adults with AML, as well as emerging data that should be considered during decision making. Additionally, he reviews novel chemotherapeutic and targeted therapies being investigated for this population, including vosaroxin, CPX-351, vadastuximab (SGN-33A), and venetoclax.








Become a Member

Forgot Password?
Filter By